Health News
Stay informed with the latest health industry news from around the globe. Read about advancements in health technology, updates in health insurance, innovations in medical devices, and more. Keep up with important health trends and industry developments.
Feb 27, 2026 at 8:51 PM
The Cannabist Company Further Extends Forbearance Agreement With Senior Noteholders
CHELMSFORD, Mass.--(BUSINESS WIRE)--The Cannabist Company Holdings Inc. (Cboe CA: CBST) (OTCQB: CBSTF) (“The Cannabist Company” or the “Company”), one of the most experienced cultivators, manufacturers, and retailers of cannabis products in the United States, today announced that the ad hoc group of noteholders of the Company’s 9.25% Senior Secured Notes due December 31, 2028 and the 9.00% Senior Secured Convertible Notes due December 31, 2028 (collectively, the “Notes”), which are parties to t...
Feb 27, 2026 at 7:00 PM
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
BEIJING, China--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to th...
Feb 27, 2026 at 7:00 PM
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the compa...
Feb 27, 2026 at 6:01 PM
National Condom Month: Why Today’s Protection Is About Pleasure, Confidence and Connection, According to Sex & Relationship Expert, Dr. Deb Laino
PHILADELPHIA--(BUSINESS WIRE)--In recognition of National Condom Month, sex and relationship therapist Dr. Deb Laino is encouraging young adults to prioritize safer sex practices - not just for protection, but for the emotional and relational benefits that come with feeling secure and aligned with your partner. As conversations around consent and sexual wellness continue to evolve, Dr. Laino emphasizes that condoms are not just about prevention - they help create a shared understanding of respo...
Feb 27, 2026 at 5:30 PM
Healthpeak Properties, Inc. Announces Public Filing of Registration Statement with the SEC for Janus Living, Inc.
DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: DOC) today announced that Janus Living, Inc., a pure-play senior housing real estate investment trust (“REIT”), has publicly filed a registration statement on Form S-11 with the Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering of its shares of Class A-1 common stock. The offering is subject to market conditions, receipt of regulatory approvals, completion of related financings, completion of...
Feb 27, 2026 at 5:00 PM
Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2025. Financial Results Revenue Consolidated revenues for fiscal 2025 were $31.6 million compared to $32.0 million for fiscal 2024. The revenues for fiscal 2025 consisted of $31.4 million in processing and storage fee revenue, $54,000 in product revenue...
Feb 27, 2026 at 4:47 PM
IQVIA Releases its 2025 Sustainability Report
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today published its 2025 Sustainability Report. The report highlights IQVIA’s progress across its People, Public and Planet pillars, consistent with the company’s mission to accelerate innovation for a healthier world. IQVIA’s 2025 Sustainability Report can be downl...
Feb 27, 2026 at 4:30 PM
Novocure to Participate in 2026 Leerink Global Healthcare Conference
BAAR, Switzerland--(BUSINESS WIRE)--Novocure to Participate in 2026 Leerink Global Healthcare Conference...
Feb 27, 2026 at 4:15 PM
Prothena Announces up to $100 Million Share Repurchase Plan
DUBLIN--(BUSINESS WIRE)--Prothena announced its Board has authorized a Share Repurchase Plan so it may repurchase up to $100 million of the Company’s outstanding shares...
Feb 27, 2026 at 4:05 PM
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 23, 2026, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 41,852 shares of its common stock to 88 new non-executive employees and one non-qualified stock option award to purchase 4,965 shares of its common stock to one new non-executive employee with a grant date of Februar...
Media & Journalist Tools
From headlines to storylines—Business Wire delivers the news you need, when you need it.